Completed PHASE3 INTERVENTIONAL 3-arm NCT06108544

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

Sponsor: Takeda

Conditions Plaque Psoriasis

Interventions Apremilast Placebo TAK-279

Updated 14 times since 2023 Last updated: Nov 18, 2025 Started: Nov 6, 2023 Primary completion: Dec 6, 2024 Completion: Nov 7, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Plaque Psoriasis, this trial is completed. The trial is conducted by Takeda and has accumulated 14 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

14 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Nov 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 9 earlier versions

Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Mar 2024 — May 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2023 — Dec 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Ann Arbor, United States , Arlington, United States , Athens, Greece , Atlanta, United States , Auburn Hills, United States , Bad Bentheim, Germany , Badalona, Spain , Barcelona, Spain , Beijing, China and 159 more locations